{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:56:50Z","timestamp":1777521410260,"version":"3.51.4"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["1132519"],"award-info":[{"award-number":["1132519"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>\n                    There is now convincing evidence that the successful development of an effective CMV vaccine will require improved formulation and adjuvant selection that is capable of inducing both humoral and cellular immune responses. Here, we have designed a novel bivalent subunit vaccine formulation based on CMV-encoded oligomeric glycoprotein B (gB) and polyepitope protein in combination with human compatible TLR9 agonist CpG1018. The polyepitope protein includes multiple minimal HLA class I-restricted CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell epitopes from different antigens of CMV. This subunit vaccine generated durable anti-viral antibodies, CMV-specific CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell responses in multiple HLA expressing mice. Antibody responses included broad T\n                    <jats:sub>H<\/jats:sub>\n                    1 isotypes (IgG2a, IgG2b and IgG3) and potently neutralized CMV infection in fibroblasts and epithelial cells. Furthermore, polyfunctional antigen-specific T cell immunity and antiviral antibody responses showed long-term memory maintenance. These observations argue that this novel vaccine strategy, if applied to humans, could facilitate the generation of robust humoral and cellular immune responses which may be more effective in preventing CMV-associated complications in various clinical settings.\n                  <\/jats:p>","DOI":"10.1371\/journal.ppat.1010403","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T13:45:21Z","timestamp":1655991921000},"page":"e1010403","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice"],"prefix":"10.1371","volume":"18","author":[{"given":"Vijayendra","family":"Dasari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirrilee","family":"Beckett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Horsefield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Ambalathingal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2241-0353","authenticated-orcid":true,"given":"Rajiv","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"ppat.1010403.ref001","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"M Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"ppat.1010403.ref002","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection.","volume":"17","author":"A Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"ppat.1010403.ref003","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \"silent\" global burden of congenital cytomegalovirus.","volume":"26","author":"S Manicklal","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"ppat.1010403.ref004","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0042-6822(92)90200-9","article-title":"Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface","volume":"191","author":"T Compton","year":"1992","journal-title":"Virology"},{"key":"ppat.1010403.ref005","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/JVI.80.2.710-722.2006","article-title":"Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion","volume":"80","author":"BJ Ryckman","year":"2006","journal-title":"J Virol"},{"key":"ppat.1010403.ref006","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/jvi.64.3.1079-1085.1990","article-title":"Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.","volume":"64","author":"WJ Britt","year":"1990","journal-title":"J Virol"},{"key":"ppat.1010403.ref007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/viro.1993.1575","article-title":"Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells","volume":"197","author":"D Navarro","year":"1993","journal-title":"Virology"},{"key":"ppat.1010403.ref008","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1586\/erv.13.46","article-title":"Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases","volume":"12","author":"V Dasari","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"ppat.1010403.ref009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/sji.12013","article-title":"Cytomegalovirus-specific CD4 and CD8 T cell responses in infants and children","volume":"77","author":"AK Lidehall","year":"2013","journal-title":"Scand J Immunol"},{"key":"ppat.1010403.ref010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fcimb.2020.00202","article-title":"The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People.","volume":"10","author":"EY Lim","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"ppat.1010403.ref011","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jpids\/piu089","article-title":"Longitudinal Kinetics of Cytomegalovirus-Specific T-Cell Immunity and Viral Replication in Infants With Congenital Cytomegalovirus Infection.","volume":"5","author":"SF Chen","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"ppat.1010403.ref012","article-title":"Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients.","volume":"9","author":"C Sommerer","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"ppat.1010403.ref013","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3026(15)00246-X","article-title":"Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.","volume":"3","author":"R Nakamura","year":"2016","journal-title":"Lancet Haematol"},{"key":"ppat.1010403.ref014","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","volume":"68","author":"C Smith","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ppat.1010403.ref015","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1093\/infdis\/jiz447","article-title":"The Status of Vaccine Development Against the Human Cytomegalovirus","volume":"221","author":"SA Plotkin","year":"2020","journal-title":"J Infect Dis"},{"key":"ppat.1010403.ref016","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.4161\/hv.27675","article-title":"Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity","volume":"10","author":"V Dasari","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"ppat.1010403.ref017","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG Adjuvant 1018: A Case Study.","volume":"1494","author":"JD Campbell","year":"2017","journal-title":"Methods Mol Biol"},{"key":"ppat.1010403.ref018","article-title":"Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.","author":"SM Hsieh","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ppat.1010403.ref019","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/infdis\/jiv071","article-title":"Functional Exhaustion Limits CD4+ and CD8+ T-Cell Responses to Congenital Cytomegalovirus Infection","volume":"212","author":"A Huygens","year":"2015","journal-title":"J Infect Dis"},{"key":"ppat.1010403.ref020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10875-015-0139-3","article-title":"Reduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infection","volume":"35","author":"L Gibson","year":"2015","journal-title":"J Clin Immunol"},{"key":"ppat.1010403.ref021","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201504-0733OC","article-title":"Polyfunctional T-Cell Signatures to Predict Protection from Cytomegalovirus after Lung Transplantation","volume":"193","author":"LD Snyder","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"ppat.1010403.ref022","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/315022","article-title":"A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant","volume":"180","author":"RF Pass","year":"1999","journal-title":"J Infect Dis"},{"key":"ppat.1010403.ref023","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"RF Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"ppat.1010403.ref024","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"12","author":"MA Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ppat.1010403.ref025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev.immunol.23.021704.115732","article-title":"Antigen-specific memory B cell development","volume":"23","author":"LJ McHeyzer-Williams","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"ppat.1010403.ref026","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1814835116","article-title":"HCMV trimer- and pentamer-specific antibodies synergize for virus neutralization but do not correlate with congenital transmission","volume":"116","author":"AL Vanarsdall","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ppat.1010403.ref027","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1083-8791(01)80005-7","article-title":"Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.","volume":"7","author":"M Boeckh","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"ppat.1010403.ref028","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1913569","article-title":"A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection","volume":"385","author":"Eunice Kennedy Shriver National Institute of Child H, Human Development Maternal-Fetal Medicine Units N","year":"2021","journal-title":"N Engl J Med"},{"key":"ppat.1010403.ref029","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.4049\/jimmunol.172.5.3260","article-title":"Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children","volume":"172","author":"W Tu","year":"2004","journal-title":"J Immunol"},{"key":"ppat.1010403.ref030","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1073\/pnas.1704809114","article-title":"The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus","volume":"114","author":"I Murrell","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ppat.1010403.ref031","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01276-20","article-title":"Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.","volume":"94","author":"N Reuter","year":"2020","journal-title":"J Virol"},{"key":"ppat.1010403.ref032","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1038\/ncomms9176","article-title":"Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody","volume":"6","author":"S Chandramouli","year":"2015","journal-title":"Nat Commun"},{"key":"ppat.1010403.ref033","doi-asserted-by":"crossref","first-page":"e1007452","DOI":"10.1371\/journal.ppat.1007452","article-title":"Different functional states of fusion protein gB revealed on human cytomegalovirus by cryo electron tomography with Volta phase plate","volume":"14","author":"Z Si","year":"2018","journal-title":"PLoS Pathog"},{"key":"ppat.1010403.ref034","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1016\/j.vaccine.2018.07.056","article-title":"Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response","volume":"36","author":"X Cui","year":"2018","journal-title":"Vaccine"},{"key":"ppat.1010403.ref035","doi-asserted-by":"crossref","first-page":"e1005227","DOI":"10.1371\/journal.ppat.1005227","article-title":"Crystal Structure of the Human Cytomegalovirus Glycoprotein B.","volume":"11","author":"HG Burke","year":"2015","journal-title":"PLoS Pathog"},{"key":"ppat.1010403.ref036","article-title":"Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion","volume":"7","author":"Y Liu","year":"2021","journal-title":"Sci Adv"},{"key":"ppat.1010403.ref037","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.","volume":"34","author":"DI Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"ppat.1010403.ref038","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"PD Griffiths","year":"2011","journal-title":"Lancet"},{"key":"ppat.1010403.ref039","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ebiom.2019.11.005","article-title":"Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation","volume":"50","author":"I Baraniak","year":"2019","journal-title":"EBioMedicine"},{"key":"ppat.1010403.ref040","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/infdis\/jir138","article-title":"Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women","volume":"203","author":"S Sabbaj","year":"2011","journal-title":"J Infect Dis"},{"key":"ppat.1010403.ref041","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1086\/315060","article-title":"Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine","volume":"180","author":"SE Frey","year":"1999","journal-title":"J Infect Dis"},{"key":"ppat.1010403.ref042","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"CS Nelson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ppat.1010403.ref043","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"I Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ppat.1010403.ref044","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1073\/pnas.0409597102","article-title":"Human cytomegalovirus cell-to-cell spread in the absence of an essential assembly protein","volume":"102","author":"MC Silva","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ppat.1010403.ref045","doi-asserted-by":"crossref","unstructured":"Jenks JA, Nelson CS, Roark HK, Goodwin ML, Pass RF, Bernstein DI, Walter EB, Edwards KM, Wang D, Fu TM, An Z, Chan C, Permar SR. 2020. Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB\/MF59 vaccine in humans. Sci Transl Med 12.","DOI":"10.1126\/scitranslmed.abb3611"},{"key":"ppat.1010403.ref046","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4049\/jimmunol.1300483","article-title":"HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic\/H-2 class I null mice: novel versatile preclinical models of human T cell responses.","volume":"191","author":"R Boucherma","year":"2013","journal-title":"J Immunol"},{"key":"ppat.1010403.ref047","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2007-11-122622","article-title":"Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection","volume":"111","author":"KK Wynn","year":"2008","journal-title":"Blood"},{"key":"ppat.1010403.ref048","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1182\/blood.V99.10.3830","article-title":"Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation","volume":"99","author":"H Hebart","year":"2002","journal-title":"Blood"},{"key":"ppat.1010403.ref049","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s002510000271","article-title":"Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes","volume":"52","author":"J Longmate","year":"2001","journal-title":"Immunogenetics"},{"key":"ppat.1010403.ref050","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1128\/JVI.77.9.5226-5240.2003","article-title":"Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers","volume":"77","author":"R Elkington","year":"2003","journal-title":"J Virol"},{"key":"ppat.1010403.ref051","doi-asserted-by":"crossref","first-page":"11538","DOI":"10.1128\/JVI.00581-07","article-title":"Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response.","volume":"81","author":"T Crough","year":"2007","journal-title":"J Virol"},{"key":"ppat.1010403.ref052","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1128\/JVI.73.3.2099-2108.1999","article-title":"The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo.","volume":"73","author":"MP Weekes","year":"1999","journal-title":"J Virol"},{"key":"ppat.1010403.ref053","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.4049\/jimmunol.151.8.3971","article-title":"Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes","volume":"151","author":"MA Gavin","year":"1993","journal-title":"J Immunol"},{"key":"ppat.1010403.ref054","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1128\/JVI.73.10.8179-8184.1999","article-title":"Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited.","volume":"73","author":"F Kern","year":"1999","journal-title":"J Virol"},{"key":"ppat.1010403.ref055","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1128\/jvi.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.","volume":"70","author":"MR Wills","year":"1996","journal-title":"J Virol"},{"key":"ppat.1010403.ref056","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00018-004-4363-x","article-title":"Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire","volume":"62","author":"MD Nastke","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"ppat.1010403.ref057","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/1521-4141(200009)30:9<2531::AID-IMMU2531>3.0.CO;2-O","article-title":"A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening","volume":"30","author":"X Saulquin","year":"2000","journal-title":"Eur J Immunol"},{"key":"ppat.1010403.ref058","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.4049\/jimmunol.170.4.2030","article-title":"Modulation of HLA-A*0201-restricted T cell responses by natural polymorphism in the IE1(315\u2013324) epitope of human cytomegalovirus.","volume":"170","author":"V Prod\u2019homme","year":"2003","journal-title":"J Immunol"},{"key":"ppat.1010403.ref059","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/eji.200425746","article-title":"Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy","volume":"35","author":"M Rist","year":"2005","journal-title":"Eur J Immunol"}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:24:16Z","timestamp":1675902256000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010403"}},"subtitle":[],"editor":[{"given":"Mark","family":"Schleiss","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1010403","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.02.482616","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]}}}